Dahlia Tuber Extract and Bacillus subtilis Encapsulation in the Ration of Broiler Chickens: Combined Effects on Blood Fat Profile and Live Weight | Chapter 4 | Research Perspective on Biological Science Vol. 4

 

Background: Antibiotic Growth Promoter (AGP) as a growth promoter has been banned in Indonesia since 2017. This has prompted the search for alternative antibiotics to support poultry products' health, productivity, and safety. This makes probiotics, prebiotics, and synbiotics potential alternatives to replace AGP.

 

Aim of the Study: This study aims to test the effect of adding encapsulated dahlia tuber extract as a prebiotic and Bacillus subtilis as a probiotic on blood lipid profiles and live weight of broiler chicken.

 

Methodology: The research was conducted from October to December 2023, at the Poultry Cage and the Laboratory of Nutrition and Feed Science, Faculty of Animal and Agricultural Sciences, Diponegoro University, Semarang, Indonesia. In this investigation, 200 unsexed Ross strain broilers aged 8 days with an average body weight of 194.53 ± 3.46 g were used. The treatment feed was administered at the age of 8-35 days, containing encapsulated dahlia tuber extract as a prebiotic and Bacillus subtilis as a probiotic (EDTEBs). Dahlia tuber extract and Bacillus subtilis were mixed in a 50:50 ratio. The study used a completely randomised design (CRD) with 4 treatments and 5 replications, each consisting of 10 broilers. The treatment given was T0: basal ration, T1: basal ration + 0.1% EDTEBs, T2: basal ration + 0.2% EDTEBs, T3: basal ration + 0.3% EDTEBs. The parameters measured were blood cholesterol, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL) levels, and live weight. Data were analysed using the JASP program.

 

Results: The results showed that the addition of dahlia tuber extract encapsulation and Bacillus subtilis encapsulation had a significant effect on cholesterol levels (P < 0.001), triglycerides (P<0.001), HDL (P = 0.002), LDL (P = 0.001), and live weight (P < 0.001) in broilers. The addition of EDTEBs at a concentration of 0.1% yielded optimal results in reducing cholesterol, triglycerides, and LDL levels, while also increasing HDL levels and live weight in broilers.

 

Conclusion: The effectiveness of the combination of Dahlia tuber extract and Bacillus subtilis can be reduced in the digestive tract, as the bioactive compounds and probiotic bacteria may be damaged by acidic gastrointestinal conditions. The addition of encapsulated dahlia tuber extract and Bacillus subtilis at a 0.1% level improved the blood lipid profile of broiler chickens by reducing cholesterol, triglyceride, and LDL levels while increasing HDL levels and live weight. The best results were obtained in the 3% addition treatment.

 

Author (s) Details

Mulyono Mulyono
Department of Animal Science, Faculty of Animal and Agricultural Sciences, Diponegoro University, Semarang, Indonesia.

 

Istna Mangisah
Department of Animal Science, Faculty of Animal and Agricultural Sciences, Diponegoro University, Semarang, Indonesia.

 

Vitus Dwi Yunianto
Department of Animal Science, Faculty of Animal and Agricultural Sciences, Diponegoro University, Semarang, Indonesia.

 

Wafiq Afifah Maulidyah
Bachelor Study Program of Animal Science, Faculty of Animal and Agricultural Sciences, Diponegoro University, Semarang, Indonesia.

 

Please see the book here:- https://doi.org/10.9734/bpi/rpbs/v4/5521

Diabetic Cardiovascular Autonomic Neuropathy: An Approach towards Insulin Resistance, Lipids and Simvastatin| Chapter 4 | Issues and Developments in Medicine and Medical Research Vol.10

 Treatment of diabetic cardiovascular autonomic neuropathy (CAN) is a multifaceted process that includes lifestyle changes, insulin resistance reduction, optimal glycemic control, diabetic dyslipidemia management, antioxidants, vitamins, treatment of myocardial metabolic abnormalities, thrombosis, and other factors. The researchers wanted to see how simvastatin affected insulin resistance and blood lipid profile measures in patients with type 2 diabetes and the definitive stage of CAN. There were 107 patients with type 2 diabetes in the study, with 16 of them having no CAN, 19 having a subclinical stage of CAN, and 72 having confirmed CAN. Patients' median age was 53.6 0.41 years, their disease duration was 4.12 0.24 years, and their median glycated haemoglobin (HbA1c) was 7.01 percent minus 0.09 percent. The control group consisted of 14 people who were nearly healthy and did not have diabetes. Patients with definite CAN were divided into two groups for treatment: 22 patients got normal hypoglycemic medication and 20 mg of simvastatin per day in the first group; 15 individuals were in the control group. The research lasted three months. The blood glucose, HbA1c, and immunoreactive insulin (IRI) concentrations were measured. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) concentrations were used to assess lipid metabolism. The atherogenic coefficient (AC), the TG/HDL-C parameters, and the TG-glucose (TyG) index were all calculated. There was a statistically significant increase in the parameters of HbA1c, IRI, TC, TG and HOMA-IR, AC, TyG indices and decrease of TG/HDL-C and HDL-C in patients with type 2 DM with subclinical stage of CAN compared to control; increase of IRI, TG, TG/HDL-C and TyG indices in patients with type 2 DM without CAN. Patients with a confirmed stage of cardiovascular autonomic neuropathy had the most substantial atherogenic alterations. An increase in HbA1c, IRI, TC, LDL-C levels and HOMA-IR, AC indices, as well as a considerable decrease in HDL-C concentrations, describe the definitive stage of CAN (compared to patients with subclinical CAN). As a consequence of our research, we discovered that prescribing simvastatin to patients with a confirmed stage of CAN resulted in a statistically significant drop in TC, LDL-C, and TG concentrations, as well as an increase in HDL-C content (compared to 2nd, control group). The findings support the use of statins in people with type 2 diabetes mellitus and a confirmed stage of CAN.

Author(s) Details:

Dr. Samir Ajmi,
 Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.

Prof. Alexandr A. Serhiyenko,
 Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.

Victoria A. Serhiyenko,
Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.

Marta E. Hotsko,
Department of Endocrinology, Danylo Halytsky Lviv National Medical University, 79010, Lviv, Ukraine.

Please see the link here: https://stm.bookpi.org/IDMMR-V10/article/view/5814